Intravitreal Anti-VEGF Use Not Tied to Systemic Adverse Events

Share this content:
Intravitreal Anti-VEGF Use Not Tied to Systemic Adverse Events
Intravitreal Anti-VEGF Use Not Tied to Systemic Adverse Events

MONDAY, March 26, 2018 (HealthDay News) -- Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment is not associated with increased risk of systemic adverse events for patients with neovascular age-related macular degeneration, diabetic macular edema, or retinal vein occlusion, according to a review published online March 22 in JAMA Ophthalmology.

Marie Thulliez, M.D., from Bretonneau Hospital in Tours, France, and colleagues conducted a systematic review to examine systemic adverse events associated with intravitreal anti-VEGF treatments in patients with neovascular age-related macular degeneration, diabetic macular edema, or retinal vein occlusion. Twenty-one systematic reviews were retrieved; 11 of these analyzed systemic adverse events as the primary outcome.

The researchers found that, compared with control regimens, anti-VEGF treatments did not increase the risk of systemic adverse events. The risk of systemic adverse events was also not increased when treatment was given on a monthly versus as-needed schedule. In the most recent and exhaustive reviews, bevacizumab was not associated with an increase in the risk of systemic adverse events compared with ranibizumab. In patients with age-related macular degeneration, ranibizumab may be associated with increased risk of nonocular hemorrhage compared with control treatments.

"This overview of reviews and meta-analyses suggest that anti-VEGF treatments do not increase the risk of systemic adverse events, but that caution might be advisable in older patients with age-related macular degeneration who may be at higher risk of hemorrhagic events when receiving ranibizumab," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves First Customizable Insulin Pump

FDA Approves First Customizable Insulin Pump

Product works by delivering insulin under the skin at set or variable rates

Sepsis Common in Terminal Hospitalizations, Discharges

Sepsis Common in Terminal Hospitalizations, Discharges

Most common underlying causes of death in sepsis are solid and hematologic cancers, chronic heart disease

Fewer Older Men Assessed, Treated for Osteoporosis

Fewer Older Men Assessed, Treated for Osteoporosis

Fewer older men than women, even with higher risk, undergo DXA screening, 25(OH)D measurement

is free, fast, and customized just for you!




Already a member?

Sign In Now »